Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria

Frontline evaluation: Atezolizumab–bevacizumab versus lenvatinib for BCLC stage B hepatocellular carcinoma exceeding the up‐to‐seven criteria

Abstract Introduction This study aimed to evaluate the efficacy and safety of atezolizumab combined with bevacizumab (Atez/Bev) compared to lenvatinib (LEN) as first‐line systemic therapy for patients with Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma (HCC) exceeding the up‐t...

Full description

Saved in:
Bibliographic Details
Main Authors: Masamichi Kimura, Koji Nishikawa, Jun Imamura, Kiminori Kimura
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
atezolizumab
Barcelona clinic liver cancer stage B
bevacizumab
hepatocellular carcinoma
lenvatinib
Online Access:https://doi.org/10.1002/cam4.70217
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70217

Similar Items